Cue Operating Cycle from 2010 to 2026
| CUE Stock | USD 0.29 0 0.72% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 42.71 | Current Value 40.58 | Quarterly Volatility 71.34716329 |
Check Cue Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cue Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 1.2 M or Selling General Administrative of 12.1 M, as well as many indicators such as Price To Sales Ratio of 7.22, Dividend Yield of 0.0 or PTB Ratio of 6.55. Cue financial statements analysis is a perfect complement when working with Cue Biopharma Valuation or Volatility modules.
Cue | Operating Cycle | Build AI portfolio with Cue Stock |
Analyzing Cue Biopharma's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Cue Biopharma's current valuation and future prospects.
Latest Cue Biopharma's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Cue Biopharma over the last few years. It is Cue Biopharma's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cue Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Cue Operating Cycle Regression Statistics
| Arithmetic Mean | 130.56 | |
| Geometric Mean | 104.55 | |
| Coefficient Of Variation | 54.65 | |
| Mean Deviation | 65.69 | |
| Median | 164.02 | |
| Standard Deviation | 71.35 | |
| Sample Variance | 5,090 | |
| Range | 179 | |
| R-Value | (0.86) | |
| Mean Square Error | 1,432 | |
| R-Squared | 0.74 | |
| Significance | 0.000011 | |
| Slope | (12.12) | |
| Total Sum of Squares | 81,447 |
Cue Operating Cycle History
About Cue Biopharma Financial Statements
Cue Biopharma stakeholders use historical fundamental indicators, such as Cue Biopharma's Operating Cycle, to determine how well the company is positioned to perform in the future. Although Cue Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cue Biopharma's assets and liabilities are reflected in the revenues and expenses on Cue Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cue Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 42.71 | 40.58 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out the analysis of Cue Biopharma Correlation against competitors. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Will Biotechnology sector continue expanding? Could Cue diversify its offerings? Factors like these will boost the valuation of Cue Biopharma. Projected growth potential of Cue fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cue Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.41) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
Cue Biopharma's market price often diverges from its book value, the accounting figure shown on Cue's balance sheet. Smart investors calculate Cue Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cue Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cue Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cue Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.